Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 5/20 | 0.48 |
| ▸ | HRH2 | P25021 | 12/20 | 0.47 |
| ▸ | HRH1 | P35367 | 12/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245870 | 0.88 | HRH2 (0.45) | KCNA5HRH2HRH1HRH3KDM4E | |
| SCHEMBL7252363 | 0.87 | HRH2 (0.48) | KCNA5HRH2HRH1HRH3 | |
| SCHEMBL7245432 | 0.86 | HRH2 (0.43) | KCNA5HRH2HRH1HRH3MEN1 | |
| SCHEMBL7243497 | 0.86 | HRH2 (0.43) | KCNA5HRH2HRH1HRH3MEN1 | |
| SCHEMBL7250880 | 0.86 | HRH2 (0.46) | KCNA5HRH2HRH1HRH3 | |
| SCHEMBL7244184 | 0.86 | HRH2 (0.43) | KCNA5HRH2HRH1HRH3 | |
| SCHEMBL7245961 | 0.86 | HRH2 (0.45) | KCNA5HRH2HRH1HRH3 | |
| SCHEMBL7248238 | 0.86 | HRH3 (0.38) | HRH3KDM4EMEN1 | |
| SCHEMBL7251556 | 0.85 | HRH2 (0.42) | KCNA5HRH2HRH1HRH3MEN1 | |
| SCHEMBL7243245 | 0.85 | HRH2 (0.44) | KCNA5HRH2HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | KCNA5 60/4885HRH2 321/4885HRH1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.